Beta-Blockers: A Complete Guide
Beta-blockers reduce heart rate and blood pressure by blocking beta-adrenergic receptors. They remain foundational drugs in cardiology, used for hypertension, heart failure, arrhythmias, and post-MI prophylaxis.
## What Are Beta-Blockers?
Beta-blockers (beta-adrenergic antagonists) inhibit the action of catecholamines -- epinephrine and norepinephrine -- at beta-adrenergic receptors. Discovered by Sir James Black in 1964, they became one of the most widely prescribed drug classes in cardiovascular medicine.
## Receptor Subtypes
There are three main beta-receptor subtypes relevant to pharmacology:
- **Beta-1 (B1)** -- Predominant in the heart. Blockade reduces heart rate (negative chronotropy), contractility (negative inotropy), and conduction velocity (negative dromotropy).
- **Beta-2 (B2)** -- Found in bronchial smooth muscle, vascular smooth muscle, and the liver. Blockade can cause bronchoconstriction and mask hypoglycemia.
- **Beta-3 (B3)** -- Present in adipose tissue, involved in lipolysis and thermogenesis. Less clinically relevant for current beta-blockers.
## Classification
**Selective (beta-1 preferring):** Metoprolol, atenolol, bisoprolol, nebivolol. Preferred in patients with asthma or diabetes because they spare beta-2 receptors at lower doses. Selectivity is dose-dependent and diminishes at higher doses.
**Non-selective (beta-1 + beta-2):** Propranolol, nadolol, timolol. Propranolol also crosses the blood-brain barrier readily, giving it utility in migraine prophylaxis, performance anxiety, and essential tremor.
**Combined alpha/beta blockers:** Carvedilol, labetalol. Carvedilol blocks alpha-1, beta-1, and beta-2 receptors and has antioxidant properties. Labetalol is preferred for hypertensive emergencies in pregnancy.
## Clinical Uses
- **Hypertension** -- No longer first-line monotherapy per most guidelines, but valuable in combination and in patients with compelling indications (post-MI, heart failure).
- **Heart failure with reduced ejection fraction (HFrEF)** -- Bisoprolol, carvedilol, and metoprolol succinate are evidence-based choices that reduce mortality.
- **Post-myocardial infarction** -- Reduce reinfarction risk and sudden cardiac death.
- **Arrhythmias** -- Rate control in atrial fibrillation; suppression of catecholamine-driven arrhythmias.
- **Other** -- Migraine prophylaxis (propranolol), portal hypertension (nadolol, carvedilol), thyrotoxicosis symptom control.
## Adverse Effects and Precautions
Common side effects include fatigue, cold extremities, bradycardia, and sexual dysfunction. Abrupt withdrawal can trigger rebound tachycardia and hypertension due to receptor upregulation -- doses should always be tapered.
Contraindications include severe bradycardia, decompensated heart failure, second- or third-degree heart block, and severe bronchospasm. Use caution in diabetes because beta-blockers can mask tachycardia during hypoglycemia.
## Key Takeaways
- Beta-blockers reduce mortality in heart failure and post-MI when titrated carefully.
- Selectivity for beta-1 matters most in patients with reactive airway disease or diabetes.
- Never stop beta-blockers abruptly -- always taper over 1-2 weeks.
- Newer agents like nebivolol add nitric oxide-mediated vasodilation with fewer metabolic effects.